Physician profile
Sandra Forde
NPI 1356397681
$4,265.87
in general payments reported to CMS, 2019-2025
24 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $256 · 2021: $835 · 2022: $978 · 2023: $747 · 2024: $855 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,882.41 |
| Education | $180.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $617.29 | 2020-2025 | Rayaldee |
| Dexcom, INC. | $605.92 | 2021-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $405.37 | 2019-2025 | Ozempic, Rybelsus |
| Vanda Pharmaceuticals INC. | $379.05 | 2021-2023 | Hetlioz, Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $377.57 | 2021-2024 | |
| Lilly USA, LLC | $351.94 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $257.66 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $155.73 | 2019-2021 | |
| Medtronic, INC. | $148.94 | 2022-2024 | Minimed 780g |
| Boston Scientific Corporation | $140.75 | 2021-2022 | |
| Abbott Laboratories | $136.07 | 2019-2024 | Freestyle Libre 3 |
| Global Blood Therapeutics, INC. | $126.78 | 2020-2021 | |
| Mannkind Corporation | $118.50 | 2022 | |
| Fresenius USA Marketing, INC. | $73.41 | 2022-2023 | Velphoro, Korsuva |
| Merck Sharp & Dohme LLC | $72.19 | 2020-2025 | Verquvo, Capvaxive |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $59.41 | 2019-2023 | |
| Ardelyx, INC. | $48.08 | 2023-2025 | Ibsrela |
| Intra-Sana Laboratories | $41.78 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Otsuka America Pharmaceutical, INC. | $34.29 | 2023-2024 | Jynarque |
| Takeda Pharmaceuticals U.S.A., INC. | $29.58 | 2021 | |
| Sanofi Pasteur INC. | $24.59 | 2020 | |
| Ani Pharmaceuticals, INC. | $21.79 | 2024 | Purified Cortrophin Gel |
| Corcept Therapeutics | $21.39 | 2025 | Korlym |
| Exact Sciences Corporation | $17.79 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Forde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.